Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.94
- Piotroski Score 3.00
- Grade Equal-Weight
- Symbol (ABVX)
- Company Abivax SA American Depositary Shares
- Price $10.45
- Changes Percentage (-4.79%)
- Change -$0.53
- Day Low $10.36
- Day High $10.86
- Year High $17.02
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $42.50
- High Stock Price Target $43.00
- Low Stock Price Target $42.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.73
- Trailing P/E Ratio -3.83
- Forward P/E Ratio -3.83
- P/E Growth -3.83
- Net Income $-147,740,000